Prestige Consumer Healthcare Inc.

PBH Healthcare Drug Manufacturers Specialty & Generic

Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.

Revenue
+22.7%
EPS
−38.4%
Free cash flow
−38.2%
Total debt
+100.9%

Quarter to September 2026, against a year earlier

43.42 0.90 −2.03%
Market cap
$2.1B
P/E
13.7×
Fwd P/E
11.7×
Dividend yield
—
F-score
5/9
Altman Z
2.48
Beneish M
−2.53
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26 From the 10-Q filed 5 Nov
P/E ratio

+8 more quarters

16.19 15.04 13.17 14.07
P/S ratio
2.68 2.64 2.03 1.87
P/FCF ratio
11.05 11.65 9.53 10.17
P/Operating CF
37.73 67.04 31.69 57.54
P/B ratio
1.61 1.52 1.17 1.12
EV/Sales
3.58 3.52 3.79 3.57
EV/EBITDA
11.16 11.18 12.92 12.59
EV/FCF
14.80 15.54 17.80 19.45
Current Ratio
3.11 3.57 3.23 2.92
Net Debt/EBITDA
10.93 11.25 31.52 (0.49)
Debt/Equity
0.58 0.54 1.06 0.00
Earnings Yield
6.18% 6.65% 7.59% 7.11%
Free Cash Flow Yield
9.05% 8.58% 10.49% 9.83%
Free Cash Flow per Share
1.57 0.78 1.41 0.72
Book value per Share
38.21 38.95 40.38 40.94
Free Cash Flow
75.26 37.63 67.09 34.24
EV/EBIT
12.26 12.38 14.44 14.31
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026